GlobeNewsWire
22 Jul 2026, 02:46 UTC · 1h ago
Dyne Therapeutics Announces Pricing of Upsized $375 Million Public Offering of Common Stock
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
GlobeNewsWire
22 Jul 2026, 02:46 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
Dyne Therapeutics has priced an upsized public offering of 18.3 million shares of common stock at $20.50 per share. — Public offerings typically lead to immediate share price dilution and can create short-term downward pressure on the stock.
-0.40The company expects to raise gross proceeds of approximately $375.15 million from the offering. — Significant capital infusion strengthens the balance sheet of a clinical-stage biotech company, reducing immediate liquidity risk.
+0.30Underwriters have been granted a 30-day option to purchase an additional 2.745 million shares. — The potential for additional share issuance increases the total possible dilution for existing shareholders.
-0.10Which stocks this story touches
Continue reading
6 related stories
Search tags
The company is successfully raising a significant amount of capital through an upsized public offering to fund its clinical programs.
Morgan Stanley is serving as a joint book-running manager for the public offering, generating fee income.
Evercore is serving as a joint book-running manager for the public offering, generating fee income.
Jefferies is serving as a joint book-running manager for the public offering, generating fee income.
Raymond James is serving as a joint book-running manager for the public offering, generating fee income.
[a_to_b] Morgan Stanley is acting as a joint book-running manager for Dyne Therapeutics' public offering.
[a_to_b] Evercore is acting as a joint book-running manager for Dyne Therapeutics' public offering.
[a_to_b] Raymond James is acting as a joint book-running manager for Dyne Therapeutics' public offering.
[a_to_b] Jefferies is acting as a joint book-running manager for Dyne Therapeutics' public offering.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
GlobeNewsWire
2h ago
